once-daily pill halved people’s risk of dying from a common lung cancer when they took the drug after tumour-removal surgery, new trial data shows. Made by the biopharmaceutical company AstraZeneca, Tagrisso, also known as osimertinib, reduced the five-year risk
A lung cancer pill drastically cuts the risk of death after surgery
Jul 06, 2023
1 minute
You’re reading a preview, subscribe to read more.
Start your free 30 days